目的：探讨曲妥珠单抗辅助化疗对HER-2过度表达老年性乳腺癌的安全性及临床疗效。方法：选取我院32例HER-2过表达的老年乳腺癌患者,均采用乳腺癌根治术联合曲妥珠单抗辅助治疗,观察其临床疗效及曲妥珠单抗辅助治疗安全性。结果：26例曲妥珠单抗治疗超过1年(81.3%),平均曲妥珠单抗维持治疗时间9.5个月(2～12个月),3例由于毒副作用停止曲妥珠单抗治疗。本组患者生存率75.0%(24/32),死亡率25.0%(8/32),其中肿瘤死亡9.4%(3/32),非肿瘤死亡18.7%(6/32)。治疗后未复发率68.7%(22/32),2例出现远处转移。全组无治疗性死亡,患者不良反应以食欲不振、恶心呕吐、脱发及色素沉着为最常见,患者大都可耐受。结论：曲妥珠单抗作为辅助治疗能提高HER-2高表达的老年乳腺癌患者的治疗有效率,延长复发时间,也延长了患者生存时间,且不良反应较易耐受。%Objective: To discuss Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients. Methods:Choose 32 elderly patients of breast cancer with HER-2-overexpressing, all treated by curative surgery and adjuvant trastuzumab, and observe its clinical curative effect and security. Results:A total of 26 patients (81.3%) completed 1-year trastuzumab treatment. The median treatment duration was 9.5 months (range 2~12 months). Three discontinued or interrupted treatment after experiencing toxicity. The survival rate was 75.0%(24/32), the death rate 25.0%(8/32), in which cancer death was 9.4%(3/32), the cancer death 18.7%(6/32). treatment without recurrence rate was 68.7%(22/32), 2 cases appeared distant metastases. No case dead in the progress of treatment, and the most common adverse reactions were loss of appetite, nausea, vomiting, hair loss and pigmentation, which most patients could tolerate. Conclusion:Trastuzumab can improve the rate of treatment HER-2-overexpressing elderly breast cancer patients, extended the time of relapse and survival time, adverse reactions to tolerate more easily.
展开▼
